LattixOrigin

Network Bio is a Palo Alto, California biotechnology company founded in 2022 that builds disease-specific AI models from human biological data. Its vertically integrated platform combines a biological research network that sources, links and structures tissue, blood and longitudinal clinical outcomes from leading U.S. academic medical centers (Mass General Brigham, University of Pennsylvania, Duke University, University of Colorado Anschutz and UCSF, spanning 500,000+ patients across oncology, immunology, metabolic and cardiovascular disease) into AI-ready datasets, with a bio-native AI architecture purpose-built to learn from multimodal biological data, overcome technical confounders and batch effects, and generate interpretable representations of disease biology that generalize across diseases, tissues and modalities.

Undisclosed · $50M · 2026-08

Enveda Biosciences, founded in 2019 in Boulder, USA, analyzes molecules produced by living organisms to build a large chemical information database for developing treatments for diseases such as atopic dermatitis and asthma.

Series D+ · $845M · 2026-09 · Valuation $2.0B

Ecotone (Ecotone AI) is an AI genomics company based in San Francisco, with a team in Brooklyn, New York, founded in 2023 by eMalick G. Njie. It trains genome foundation models that read the human genome as a 'first language'; its flagship model dnaSORA is a diffusion transformer combining generative and discriminative capabilities to pinpoint disease-causing sequences among roughly 3 billion bases, which the company says can surface disease mechanisms from dozens rather than thousands of patient samples. It targets pharma and biotech drug developers working on rare genetic diseases and aims to cut genome-interpretation costs.

Convergen (Suzhou Wosheng Biopharmaceutical Co., Ltd.), founded in December 2020 and headquartered in Suzhou, China, develops the TrimTAC platform: bifunctional degraders leveraging the E3 ubiquitin ligase TRIM21 to selectively clear pathogenic multimeric protein aggregates while sparing monomeric proteins. The technology originates from the 2024 Cell paper by the lab of Scientific Co-Founder Dr. Ting Han (Associate Investigator, National Institute of Biological Sciences, Beijing). CEO and founder is Dr. Jinquan Sun. Pipeline targets neurodegenerative diseases such as Alzheimer's and aggregation-driven autoimmune conditions.

Seed · $25M · 2026-08

Insilico Medicine, founded in 2019 in Shanghai, China, is a developer of drug candidates for anti-aging and cancer treatment.

Series D+ · $210M · 2025-03

AIPher is an AI-native drug discovery company incubated by Tsinghua University’s Institute for AI Industry Research (AIR), founded in Beijing in 2026, building drug foundation models (DrugCLIP) and an AI drug-discovery agent engine (PharmAgents) to advance small-molecule and peptide programs, with its lead in-house pipeline at Pre-PCC stage.

Angel · 2026-09

Helical, founded in 2024 in Luxembourg, converts biological AI foundation models into reproducible drug discovery workflows for pharmaceutical teams.

Seed · $20M · 2026-04

AI-native drug discovery using patient-derived disease models to design small-molecule therapies for cancer and fibrosis.

Pre-Seed · $3M · 2026-07

OutSee, founded in 2022 in Cambridge, UK, uses AI to analyze individual genomes and predict disease biological mechanisms, helping drug developers identify new therapeutic targets. Its core platform, Nomaly, is a proprietary AI engine developed by founder and CEO Dr. Julian Gough that employs hypothesis-free modeling to predict disease and phenotypes directly from individual genomes, enabling insights from smaller cohorts or previously intractable datasets.

Seed · $2M · 2025-06

Deep Cell is an AI-pharma and virtual-cell startup whose core approach deeply fuses 'AI + multi-scale physical mechanics'. Built around a molecular-interaction foundation model, it develops a high-precision molecular-design platform and a virtual-cell world model spanning a unified 'multi-omics - structure - interaction - energy - dynamics - function' framework, aiming to link scales from molecules to pathways and from local cell states to whole-cell states and disease phenotypes. Founder Chen Xindong holds a Tsinghua doctorate under academician Feng Xiqiao, with work published in PNAS and ACS Nano. The company is an early-stage platform with undisclosed pipelines.

Seed · $14M · 2026-08

According to a TechCrunch report dated July 14, 2026 (source unspecified), former OpenAI researcher Miles Wang is preparing to launch an AI drug discovery startup. The company name, headquarters, and website remain undisclosed, and the funding details are unconfirmed rumors.

Galux, founded in 2020 in Seoul, operates GaluxDesign, an AI and physics-based platform for protein and antibody design in drug development.

Series B · $58M · 2026-02